The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...
New research presented at the ASCO Annual Meeting 2026 demonstrates that biomarker-guided lung cancer treatment offers ...
About half of people diagnosed with metastatic non-small-cell lung cancer never receive treatment, despite advances in ...
Understanding lung cancer, its stage, and treatment intent is crucial for informed decision-making and patient empowerment. Patients should be aware of therapy rationale, potential side effects, and ...
ASCO guidance for stage IV EGFR-mutant NSCLC supports initial combination regimens (osimertinib plus chemotherapy; amivantamab plus lazertinib) to improve disease control relative to monotherapy.
Pfizer Inc. said an experimental drug failed to improve survival in patients with an advanced form of lung cancer that couldn ...
Pfizer said on Monday its drug for ​a type of lung cancer ‌missed the main goal of improving survival in patients compared to ...
12don MSN
When lung cancer progressed despite treatment, a genomic clue helped doctors rethink the approach
A 70-year-old woman's advanced lung cancer treatment transformed after genomic testing revealed a MET exon 14 skipping ...
The ION Intuitive system allows thoracic surgeons to reach deeper lung nodules with greater precision, improving early lung ...
It's natural to feel afraid after a lung cancer diagnosis. But there's also real reason for hope, as treatment for lung cancer has improved dramatically in the last decade. (DigitalVision/Getty Images ...
Lung adenocarcinoma is the most common type of lung cancer diagnosed in the U.S. Just over half of all non-small-cell lung cancers (NSCLCs) are adenocarcinomas. Finding out that you're at risk of lung ...
I had no family history of lung disease, was a non-smoker and was only 39, so the pulmonologist thought it was very unlikely ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results